Currently, there are 52.34M common shares owned by the public and among those 42.67M shares have been available to trade.
The company’s stock has a 5-day price change of 22.61% and 34.61% over the past three months. JANX shares are trading 457.88% year to date (YTD), with the 12-month market performance up to 562.17% higher. It has a 12-month low price of $7.79 and touched a high of $65.60 over the same period. JANX has an average intraday trading volume of 688.23K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 18.77%, 20.02%, and 32.80% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Janux Therapeutics Inc (NASDAQ: JANX) shares accounts for 86.65% of the company’s 52.34M shares outstanding.
It has a market capitalization of $3.14B and a beta (3y monthly) value of 3.30. The earnings-per-share (ttm) stands at -$1.18. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.06% over the week and 7.06% over the month.
Earnings per share for the fiscal year are expected to increase by 4.30%, and -55.31% over the next financial year.
Looking at the support for the JANX, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on Dec-04-24, with the firm’s price target at $63-$70. BTIG Research coverage for the Janux Therapeutics Inc (JANX) stock in a research note released on December 04, 2024 offered a Buy rating with a price target of $100. Leerink Partners was of a view on November 22, 2024 that the stock is Outperform, while UBS gave the stock Buy rating on October 24, 2024, issuing a price target of $69. Stifel on their part issued Buy rating on September 06, 2024.
